TheraVet Is Strengthening Its Corporate Governance With the Appointment of Three New Independent Board Members
16 Décembre 2021 - 7:30AM
Business Wire
Simon Wheeler is to be co-opted as an
independent director and will chair TheraVet’s Board of
Directors
Nesya Goris and Christian Schirvel will also
join the board as independent director and independent observer
respectively
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a
biotechnology company specialising in osteoarticular treatments for
animals, is strengthening its corporate governance by co-opting two
new independent directors (Simon Wheeler and Nesya Goris) and an
independent observer (Christian Schirvel). Their appointment to the
board is subject to approval by shareholders in the Company’s next
Shareholders’ General Meeting. Simon Wheeler will also replace
Lotfi Yelles Chaouche as Chairman of TheraVet’s Board of
Directors.
Enrico Bastianelli, TheraVet’s CEO, said: “We are
delighted that three new independent members of the quality of
Simon Wheeler, ,Nesya Goris and Christian Schirvel will be joining
our Board of Directors. We are confident that their experience
working in both large corporations and smaller companies in the
veterinary field, along with their expertise in animal health, will
be valuable assets as we pursue our strategic development.”
Dr Simon Wheeler, BVSc, PhD, said: “It is an honor to
join TheraVet's Board of Directors. The team has already
accomplished great things under the leadership of Enrico
Bastianelli and the governance of the Board of Directors, chaired
by Lotfi Yelles Chaouche. We are justifiably excited about the
future of TheraVet as the Company enters a commercialization phase
while continuing the clinical development of its veterinary product
portfolio. I am confident that the hard work of the TheraVet team
will continue to produce fantastic results for pets and their
owners, in association with the veterinary professionals who
provide them with high quality clinical care.”
Dr Nesya Goris, PhD in veterinary sciences, said: “The
treatments TheraVet is developing and offering in the field of
osteoarticular diseases have the potential to make a significant
impact on the quality of life of cats, dogs and horses and it is a
pleasure for me to be able to witness and hopefully contribute to
this story.”
Dr Christian Schirvel, DVM, MSc, said: “It is with great
pleasure that I am joining TheraVet’s Board of Directors. I have
worked in the veterinary pharmaceutical industry for over 30 years
and have helped deliver various projects relating to surgery in
general, oncology and osteoarthritis: high-growth segments
addressing major unmet needs in which TheraVet is building its
business. So I will bring my knowledge of the animal health market
and those who take part in it, with the aim of helping this
promising biotech company make the right strategic decisions in
terms of developing its business, selecting which projects to focus
on, building partnerships and determining its current and future
approach to marketing products.”
Biographies of the new board members
Dr Simon Wheeler, BVSc, PhD, DECVN, MBA, FRCVS, is an
expert in animal health and veterinary medicine. He has more than
20 years’ experience working for major pharmaceutical groups in
which he has held numerous executive roles, and has worked for more
than 20 years in academia. Dr Wheeler has a PhD in Veterinary
Medicine from the Royal Veterinary College and an MBA from the Open
University Business School. He is Managing Director of Veterinary
Neurology Ltd, and he previously spent 10 years at Novartis Animal
Health, including a four year period with Novartis Venture Fund. Dr
Wheeler has previously served as Chairman of the Academic Board of
the European School of Veterinary Postgraduate Studies and is a
director of Anifera Ltd, a start-up in the antimicrobial resistance
arena. He consults on veterinary neurology clinical patients.
Dr Nesya Goris, PhD, is co-founder and Chief Development
Officer at ViroVet. She has a Master in Science from the University
of Leuven and a PhD in Veterinary Sciences from the University of
Ghent. After starting her career at Belgium’s reference laboratory
for animal diseases, she became Chief Scientist at Okapi Sciences
for six years before it was taken over by Aratana Therapeutics,
where she was appointed VP Discovery Research and contributed to
the commercial launch of Galliprant, a treatment for canine
osteoarthritis. Currently, Dr Goris combines her role at ViroVet
with that of Technical and Regulatory Director at Animab BV. She is
also a member of the Board of Directors of Flanders Vaccine, an
editor for the academic journal Antiviral Research and a lecturer
at the University of Leuven in Belgium.
Dr Christian Schirvel DVM., MSc, is hugely experienced in
the field of animal health, having spent more than 30 years working
for pharmaceutical groups such as Mérieux, Merial, Vétoquinol,
Novartis and Elanco. Before joining TheraVet’s board, he was Head
of Business Development and Licensing (EMEA and APAC) at Elanco. He
also spent almost seven years at Swiss pharmaceutical group
Novartis Animal Health as Head of Business Development and
Licensing for parasiticides and therapeutic products. Previously in
his career, Christian spent nine years at Rhône Mérieux, holding
several key roles including Head of Strategic Development. He also
is an independent Consultant (Vel-Vet AH Consulting) for small and
mid-size Animal Health Companies, supporting them defining their
strategy in general. He has a degree from the University of Liège
in Belgium.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211215005910/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet Tel: +32 71 96 00 43
Julie Winand Chief Corporate Officer julie.winand@thera.vet
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 1 44 71
94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024